Skip to main content

Table 2 Treatment-related toxicities for each dose cohort during the first 16 weeks of treatment

From: Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma

Adverse events

IMRT + apatinib 250 mg

IMRT + apatinib 500 mg

 

Grade 1

Grade 2

Grade 3

Grade 1

Grade 2

Grade 3

Leukopenia

1

2

0

0

3

2

Neutropenia

2

0

0

2

3

0

Anaemia

1

0

0

1

0

0

Thrombocytopenia

0

1

0

0

4

0

ALT increased

2

0

0

2

0

0

AST increased

1

1

0

2

0

0

Hyperbilirubinemia

2

2

0

3

1

0

Hypoalbuminemia

3

0

0

0

1

0

Proteinuria

0

0

0

2

1

0

Headache

0

0

0

2

1

0

Dizziness

1

2

0

3

1

0

Fatigue

3

0

-

3

1

-

Nausea

2

0

0

3

1

0

Diarrhoea

0

0

0

1

0

0

Hand-foot syndrome

0

0

0

2

1

0

Hypertensiona

2

1

1

1

1

3

  1. Abbreviations: IMRT Intensity-modulated radiation therapy, ALT Alanine aminotransferase, AST Aspartate aminotransferase
  2. a One case of grade 3 hypertension in the apatinib 250 mg group and 3 cases of grade 3 hypertension in apatinib 500 mg group were found, all of which could be controlled to grade 0–1 and were not defined as dose-limiting toxicities in this combination treatment regimen
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us